
Finding The Right Leader For Your Company's AI Strategy
More than half of business leaders—58%—said they feel optimistic about their company performance. And while that's a substantial drop from the 75% who felt upbeat in a December survey, it's still a significant number, especially as 32% of business leaders either expect a recession this year or think we're already experiencing one.
A significant number of business leaders—44%—said they've held off on their plans for the year. Almost three-quarters say that decision is the result of policy uncertainty. And companies cite uncertain economic conditions as their top challenge, followed by tariffs. However, businesses aren't stopping at all, with 14% accelerating their plans for 2025, seeing how things go in the uncertain economy. Depending on how things pan out, this year may truly be one of the more challenging times to prove business resilience.
Policy and tariffs aside, technology advances and the rise of AI are also moving the business world. Who at your company should take the lead? Chad Hesters, CEO of executive search firm Boyden, has helped several companies figure that out and spoke with me about the process. An excerpt from our conversation is later in this newsletter.
We're taking a summer break and will not be publishing Forbes CEO next week. We'll be back on Monday, July 14. This is the published version of Forbes' CEO newsletter, which offers the latest news for today's and tomorrow's business leaders and decision makers. Click here to get it delivered to your inbox every week.
President Donald Trump holds up a chart at the "Liberation Day" trade announcement in April.Stock markets finally fully recovered last week from their early April 'Liberation Day' drop, when President Donald Trump announced his slate of sweeping tariffs on other nations. The S&P 500 and Nasdaq hit their first highs in four months this week, setting a record level for both indexes on Friday. Leading analysts aren't optimistic that the highs will keep coming, though. JPMorganChase top global strategist Dubravko Lakos-Bujas forecast the S&P will end the year 2% lower than Friday, citing the 'lagged effects of new policies (i.e., tariffs, immigration, DOGE).'
Stocks have been able to rebound because, for the most part, the tariff threat has only been just that. While Trump has announced dates by which different tariffs would go into effect, those deadlines have often been moved forward or paused to allow for negotiations. And negotiations have been ongoing, sometimes to benefit the United States. After Trump abruptly ended negotiations on Friday with Canada over that country's new digital service tax—a 3% charge on foreign tech companies for revenue generated from Canadian users—the Canadian government decided over the weekend to rescind the tax. Stocks were slightly up after markets opened Monday morning.
But tariffs—and how suddenly they may go into effect—loom large. Trump said on Friday that he holds the cards on whenever tariffs start. Many were set to begin on July 9, and Trump said he could extend it—or expedite the deadline, which he said was his preference.
Tariffs and the economic uncertainty haven't impacted prices too deeply just yet, though May's inflation inched up more than expected last month, reaching 2.7%, according to the core personal consumption expenditures index—excluding food and energy categories. Some analysts expect a continued rise in inflation as Trump's tariffs actually go into effect and raise consumer prices.
The increase is above the Federal Reserve's preferred 2% rate, so last month's numbers may show further proof that the Fed acted appropriately when it didn't lower interest rates—but Trump has been itching to dismiss Federal Reserve Chairman Jerome Powell because of his unwillingness to drop them on command. While Trump has said he will let Powell serve to the end of his term next May—even though he constantly berates him—the Wall Street Journal reported that Trump may name Powell's successor this fall, allowing a 'shadow' Fed chair to operate and share their preferred policy choices—something analysts have said would definitively undermine Powell. NOTABLE NEWS
School supplies are on display at a Target in New York City. Deb Cohn-Orbach/UCG/Universal Images Group via Getty Images
Although the 145% tariffs on China only lasted for about a month, analysts fear they will be most acutely felt at back-to-school time. A study released from PwC last week found that nearly three-fourths of U.S. families expect to spend the same amount or more on back-to-school shopping this year, writes Forbes senior contributor Joan Verdon. But this doesn't mean they intend to buy more—they're prepared for what they need to buy to be more expensive. Families are planning money-saving strategies: About two in five plan on only buying items on sale, while the same proportion is likely to shop earlier. Nearly a quarter will purchase more store-branded products, while 18% are looking to shop secondhand.
Consumer confidence continues to be down, dropping by 5.4 points this month alone, according to the latest figures from the Conference Board. The Conference Board reports that June's retreat in consumer confidence, currently at 93, declined across all age and political groups. It also was shared by most income groups. The largest decline was among Republicans. BIG MOVES
Anna Wintour at the Tony Awards earlier this month. John Nacion/Variety via Getty Images
A legendary business leader announced last week that she is stepping down from a position she's held for nearly four decades. Vogue editor-in-chief Anna Wintour, who is often associated with the fashion industry itself, is stepping back from the U.S. magazine's editorial operations, though the timeline for her exit is unclear. She will not be leaving Condé Nast, the company that publishes Vogue , and will remain its global chief content officer, as well as the editorial director of the global editions of Vogue . Condé Nast CEO Roger Lynch told the Wall Street Journal that Wintour has been working three jobs at the company since 2020, and it makes sense to step back from one of them.
Wintour has been editor of Vogue since 1988, and has been credited with igniting the magazine's appeal. She's also co-chaired the Met Gala since 1995, making it an extravagant fashion event. Her iconic persona is known far beyond the fashion world—even allegedly inspiring the infamously overbearing boss in the book and movie The Devil Wears Prada —and replacing an executive who is so well-known will be a difficult task. Forbes senior contributor Toni Fitzgerald handicaps some potential successors, but none has Wintour's name recognition outside of the publishing industry. TOMORROW'S TRENDS Who Should Be In Charge Of Your Company's AI?
Boyden CEO Chad Hesters. Copyright 2023, Gittings
As you bring AI into your company, one of the looming questions is who should oversee it. Do you need a chief AI officer? Is it a job for the CIO or CTO? Should the CEO's office be handling it? Chad Hesters, CEO of executive search firm Boyden, has worked with many leaders who are grabbling with the same questions. I spoke with him about how CEOs can find the right answer for their company. This conversation has been edited for length, clarity and continuity.
AI is something that every business is using, and many have plans to get much deeper into it. At this point, which C-suite department tends to be handling AI in companies?
Hesters: At the first phase when AI showed up, everybody said, 'AI is a thing. We must master this thing in order to become world class at whatever we do.' Followed by, 'We need a chief AI officer. We need a chief innovation officer.'
We've moved to phase two of that evolution. Companies are realizing what's more important is creating the environment for individuals, departments, functions to evolve, and the mechanisms which allow them to do that. AI right now is a set of tools that we can all use to make us more efficient or produce a better product. The more sophisticated companies, the ones that are at the leading edge, have realized that the key is to let the individual employee have some authority to understand what might be able to help them do their job better. Then design the entire system to take these ideas, feed them into the system and be able to vet [privacy and security], but still allow for that micro-level innovation.
It's like crowdsourcing innovation inside a company. Leading companies have gotten over the arrogance that you could have one officer and one function inside a company to drive all of innovation for the company, when really it's that 24-year-old that you just got out of the MBA program who says, 'Hey, I heard about this new tool. Maybe we should look at it.'
What you're seeing is the chief technology officer own the process. How do you set up the conditions inside a company that allow for good ideas to percolate and crowdsource? That's the CTO's job.
If you have a chief innovation officer, their job is to prioritize what are the areas that we need top-level capital investment to innovate in. That's the top-down approach.
You've got a top-down/bottoms-up approach to AI now. The companies that are leading seem to be approaching it from that perspective.
C-suite titles and responsibilities are always evolving. Where do you see AI going in terms of corporate responsibility? Do you see more chief AI officers in the future? Will AI get divided into different departments? Will it all come under the CIO?
You need leaders that understand that technology and innovation is not a nice-to-have. It's required for survival in today's environment. If they understand that, and are willing to try to adopt those potential efficiency gains in their functional areas and cross-functionally, you need to have the internal processes and capabilities to do it. You've got to have a chief person that knows how to conduct an innovation pipeline appropriately: responsible and safe and still allow a lot of freedom to innovate. They have to design the process, and then they have to have the actual systems in place.
Let's look at how much energy AI processes can utilize. Who owns that? If you all of a sudden are sitting on a bunch of data and you want to start crunching it and to use an AI tool, are you going to build your own data center? Are you going to co-opt it? Where do those energy prices go? Do you pass those onto your customers? Do you need it internally? What are you giving up to do that? There's always a knock-on effect. It's not just, 'Look! We've got a new tool.' When you want to roll out that new tool, that new way of doing business, you've got to bring all the other functional leaders into the room to look at the 360-approach to what it's going to do.
The energy aspect of this is fascinating when you think about sustainability and how we tie it in. How do you ensure that the AI tools you're using are not over-indexing some kind of bias that at a minimum is going to help you make poor decisions, but in a really scary world, create biases and risk and liabilities for your company?
It's almost foolish to assume you could appoint one person and call them the chief AI officer and it's all going to be fine. It's really got to be a management team mindset, and everybody's got to be at the table. Then you've got to be willing to look externally as well. You've got to bring other stakeholders.
What advice would you give to a CEO that is struggling with where to put AI leadership right now?
Don't think about AI first. Think about what are the critical competencies that your organization has to have to achieve your strategy? That's the answer to where we make investments in AI and innovation. You could outsource a lot of the secondary requirements and services your company has, but a CEO should be investing in the critical functions and capabilities it needs to achieve the strategy. When you're looking where that extra dollar of investment goes, it should go to the tools and capabilities that allow you to achieve that strategy.
It's very easy to get distracted today. There's so many cool products and AI tools out there that you could chase around, and at the end of the year have lots of new products that don't really do much for your strategy. That's the opposite of what a CEO should be doing.
In the past six to eight months, we've looked at 40 different AI tools that could help us with our key critical functions. We're staying focused on that. Only four or five made it through our innovation funnel, but that's four or five different tools we've got that are really helping us execute for our clients the tasks that they've hired us to do. And we can do it with a much higher degree of quality and faster. COMINGS + GOINGS Generic pharmaceutical giant Sun Pharma appointed Richard Ascroft as CEO of its North America operations, effective June 16. Ascroft joins the firm from Takeda Pharmaceuticals, and succeeds Abhay Gandhi in the role.
appointed as CEO of its North America operations, effective June 16. Ascroft joins the firm from Takeda Pharmaceuticals, and succeeds Abhay Gandhi in the role. Integrated health care provider CareMore Health selected Sam Wald as its new chief executive officer. Wald previously worked in leadership at WelbeHealth and Optum.
selected as its new chief executive officer. Wald previously worked in leadership at WelbeHealth and Optum. Work management platform Asana named Dan Rogers as its next CEO, effective July 21. Rogers most recently worked in the same role at LaunchDarkly, and he will succeed Asana co-founder Dustin Moskovitz, who will remain board chair.
Send us C-suite transition news at forbescsuite@forbes.com STRATEGIES + ADVICE
Every small company has its eyes on scaling up, but even the most successful startups need to pace themselves. Rapid growth doesn't look as good from the viewpoint of employees who are suddenly finding everything about their jobs changing. Here are some ways leaders can tap the brakes to make sure a company doesn't grow at a speed too quick for comfort.
Will AI displace workers and eliminate jobs, or will it transform companies to be more lucrative with different kinds of workers? Nothing is certain at this point, but leaders need to be thoughtful about how they're using the technology as the working world figures it out. QUIZ
Warren Buffett, who has pledged to give away most of his wealth, gave the largest amount in nearly 20 years to charities over the weekend. How much did Buffett donate?
A. $800 million
B. $1.7 billion
C. $3.9 billion
D. $6 billion
See if you got it right here.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
15 minutes ago
- Yahoo
Universal Music Group Files Confidentially for US Listing
(Bloomberg) -- Universal Music Group NV has filed confidentially for a US listing, which would fulfill the terms of a deal with billionaire Bill Ackman's hedge fund Pershing Square. Why the Federal Reserve's Building Renovation Costs $2.5 Billion Salt Lake City Turns Winter Olympic Bid Into Statewide Bond Boom Milan Corruption Probe Casts Shadow Over Property Boom How San Jose's Mayor Is Working to Build an AI Capital The Amsterdam-listed firm submitted documents to the US Securities & Exchange Commission relating to a proposed offering by certain of its shareholders, according to a statement Monday. The world's largest music company won't receive any proceeds from the sale. Universal Music's shares rose 0.9% to €27.31 apiece at 9:51 a.m. in European trading on Tuesday, leading gains in Amsterdam's AEX Index. The filing comes after Universal said in January it would plan the US listing in order to satisfy an agreement with Pershing Square, a statement at the time showed. Ackman resigned from Universal's board in May, citing increasing demands on his time from commitments including his appointment as Executive Chairman of Howard Hughes Holdings Inc. Universal Music, which is the label for artists including Taylor Swift, had in recent months resisted Ackman's push to move its domicile and delist it from Euronext Amsterdam. Pershing Square had urged Universal Music to pursue a US listing, saying it would substantially increase the valuation of the shares. A group of shareholders affiliated with Pershing Square in March raised more than €1.3 billion ($1.5 billion) from the sale of about a 2.7% stake in the Hilversum, Netherlands-headquartered firm, Bloomberg News reported. --With assistance from Sarah Jacob. (Updates with share move in third paragraph.) Elon Musk's Empire Is Creaking Under the Strain of Elon Musk A Rebel Army Is Building a Rare-Earth Empire on China's Border Thailand's Changing Cannabis Rules Leave Farmers in a Tough Spot How Starbucks' CEO Plans to Tame the Rush-Hour Free-for-All What the Tough Job Market for New College Grads Says About the Economy ©2025 Bloomberg L.P.
Yahoo
15 minutes ago
- Yahoo
Telix Reports $204M Revenue, Up 63% YOY
MELBOURNE, Australia and INDIANAPOLIS, July 22, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, 'Telix') today provides an update on its commercial and operational performance for the quarter ended 30 June 2025 (Q2 2025). All figures are in USD unless stated otherwise. Q2 2025 Highlights Q2 2025 unaudited group revenue of approximately $204 million, up 63% year-over-year. FY 2025 revenue guidance of $770 million to $800 million is reaffirmed. Gozellix® launched in the U.S. and commercial dose deliveries commenced. Gozellix has been assigned a Level II HCPCS code1 (effective 1 October 2025), a prerequisite for receiving Transitional Pass-Through payment status. ProstACT™ Global Phase 3 trial milestone – all 30 patients consented for Part 1. Global expansion with regulatory approvals to expand the trial into China, Japan and Canada. Q2 2025 Revenue (Unaudited) Revenue$M Q2 2025 Q2 2024 Variation Q1 2025 Variation Group revenue 204 125 63% 186 10% Global Illuccix® revenue 154 123 25% 151 2% RLS revenue1 46 - - 332 39% Commentary and business highlights Dr. Christian Behrenbruch, Managing Director and Group CEO, Telix, stated, 'Dose volumes for Illuccix rose 7% quarter-on-quarter in the U.S., reinforcing the strength of our market position and continued customer demand. Despite emerging competitive pricing pressure, we have effective strategies in place to manage impact to average selling price. This includes the recent launch of Gozellix which has been assigned a HCPCS code, a crucial reimbursement milestone towards pass-through status. We continue to show positive momentum across multiple assets in our therapeutic pipeline, including achievement of a key recruitment milestone in our ProstACT Global Phase 3 trial.' Therapeutics business TLX591 (177Lu-rosopatamab tetraxetan): Telix has consented all 30 patients required to complete Part 1 of ProstACT Global, the Phase 3 trial of its lead prostate cancer therapy candidate. Patients in two of the three arms (abiraterone and enzalutamide as standard of care) have completed dosing. An interim readout of safety and dosimetry will follow the completion of patient dosing, monitoring and data analysis. The trial is proceeding seamlessly into Part 2 at existing ex-U.S. sites and additional regulatory approvals have been obtained to commence the trial in China, Canada and Japan4. TLX592 (225Ac-PSMA-RADmAb): Telix has submitted a Human Research Ethics Committee (HREC) application in Australia for a Phase 1, first-in-human therapeutic study of a targeted alpha therapy in advanced metastatic castration resistant prostate cancer. TLX101 (131I-iodofalan, or 131I-IPA): Telix received HREC approval in Australia to commence IPAX BrIGHT, an international pivotal trial. An IPAX BrIGHT Clinical Trial Application (CTA) has also been submitted in Europe. TLX250 (¹⁷⁷Lu-DOTA-girentuximab): STARLITE-15 is enrolling patients. This Phase 1b/2 clinical trial is investigating the use of TLX250 in combination with cabozantinib and nivolumab, in clear cell renal cell carcinoma (ccRCC). Trial submission is in preparation for a pivotal trial of TLX250 as a monotherapy in advanced metastatic ccRCC, initially launching ex-U.S. TLX090 (¹⁵³Sm-DOTMP): In July, Telix submitted an Investigational New Drug (IND) application for a Phase 1 bridging study for Telix's therapeutic candidate for the palliation of bone pain in patients with osteoblastic metastatic disease to the bone. Precision Medicine businessTelix received country-level approvals for Illuccix in France, Finland, Ireland, Sweden, Germany, Portugal, Greece, the Czech Republic, Belgium and Italy in Q2 and is launching on a market-by-market basis, as reimbursement is secured. Telix has completed enrolment of the Illuccix China Phase 3 study6, which will be used to file a marketing authorization in China in Q4 2025. Telix has received HREC approval in Australia and filed an IND with the FDA in the U.S. for a Phase 3 clinical trial aimed at expanding the label indication for Illuccix and Gozellix. The BiPASS study7 will evaluate the performance of MRI8 combined with PSMA PET9 imaging for detection and diagnosis of prostate cancer, which is designed to reduce the need for invasive biopsies. Telix has submitted a Prior Approval Supplement (PAS) to update the U.S. Prescribing Information for Illuccix. The proposed label expansion includes patient selection for radioligand therapy (RLT) in the pre-taxane setting. The prescribing information is expected to be updated, following FDA's review of the submission10. As part of product lifecycle management strategy, Telix announced a novel PET11 radiochemistry solution based on fluorine-18 (18F)-aluminium fluoride (AlF), branded AlFluor™12. The platform technology enables flexible radiolabeling of PSMA13 with either AlF or gallium-68 (68Ga). As part of the platform's development, Telix signed a strategic agreement with University Hospital Ghent and Ghent University for a novel [18F]AlF-PSMA-11 targeting agent, including extensive clinical data to enable a U.S. registration trial. Pixclara®14 (TLX101-CDx, 18F-floretyrosine or 18F-FET): A successful Type A meeting was held with the FDA on 24 June 2025, to agree on a path forward for resubmitting the New Drug Application (NDA) for Telix's brain cancer imaging candidate. Zircaix®15 (TLX250-CDx, 89Zr-DFO-girentuximab): The Company continues to progress a Biologics License Application (BLA) with the FDA for its kidney cancer PET imaging candidate. The PDUFA16 date remains 27 August 2025. Telix Manufacturing Solutions (TMS) Telix announced its Good Manufacturing Practice (GMP) manufacturing facility in Yokohama, Japan. Telix's first cyclotron facility in the Asia Pacific region represents a significant milestone in the Company's global manufacturing strategy. It will serve as a hub for commercial and clinical drug product supply, and future research and development in the region. The TMS facility in Brussels South (Seneffe), Belgium, produced its first GMP commercial radiopharmaceutical doses, marking the formal launch of Telix's radiopharmaceutical manufacturing capability in Europe. Corporate update Telix has received a subpoena from the U.S. Securities and Exchange Commission (SEC) seeking various documents and information primarily relating to the Company's disclosures regarding the development of the Company's prostate cancer therapeutic candidates. The Company is fully cooperating with the SEC and is in the process of responding to the information request. At this stage, this matter is a fact-finding request. The Company has elected to notify the Australian Securities and Investments Commission of the SEC's information request. Telix's policy is not to discuss any details of an ongoing regulatory inquiry. The information request from the SEC does not mean that Telix or anyone else has violated United States federal securities laws or that the SEC has a negative opinion of any person, entity or security. We cannot predict when this matter will be resolved or what (if any) action the SEC may take following the conclusion of this investigation. While the matter is ongoing, Telix will continue with its clinical development programs relating to its prostate cancer therapy candidates, in the ordinary course of business. The information request does not extend to Telix's commercial and late-stage precision medicine products including Illuccix, Gozellix, Zircaix, Pixclara and Scintimun®. FY 2025 guidance Telix confirms FY 2025 revenue guidance of $770 million to $800 million17. Guidance reflects revenue from Illuccix sales in jurisdictions with a marketing authorization, and 11 months of revenue contribution from RLS18. Telix confirms research and development (R&D) expenditure guidance, expecting a year-over-year increased investment range for FY 2025 of 20% to 25% compared to FY 2024. Guidance disclaimer The stated revenue guidance is based on expected global and domestic economic conditions and is subject to known and unknown risks, uncertainties and other factors that may cause our actual results to differ materially. As such, investors are cautioned not to place undue reliance on this guidance and in particular Telix cannot guarantee a particular result. In compiling financial forecasts, a number of key variables that may have a significant impact on guidance have been identified and are listed below. Key variables that could cause actual results to differ materially include: the success and timing of research and development activities; decisions by regulatory authorities regarding approval of our products as well as their decisions regarding label claims; competitive developments affecting our products; the ability to successfully market new and existing products; difficulties or delays in manufacturing; trade buying patterns and fluctuations in interest and currency exchange rates; legislation, regulation, or policy that affects product production, distribution, pricing, reimbursement, access or tax; acquisitions and divestitures; research collaborations; litigation or government investigations; and Telix's ability to protect its patents and other intellectual property. See the Legal Notices section below for additional information, risks and assumptions. About Telix Pharmaceuticals Limited Telix is a biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. Telix is headquartered in Melbourne, Australia, with international operations in the United States, Brazil, Canada, United Kingdom, Europe (Belgium and Switzerland), and Japan. Telix is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (NASDAQ: TLX). Telix's prostate imaging product, gallium-68 (68Ga) gozetotide injection (also known as 68Ga PSMA-11 and marketed under the brand name Illuccix®), has been approved by the FDA19, and in multiple markets globally. Gozellix® (kit for the preparation of gallium-68 (68Ga) gozetotide injection) has been approved by the FDA20. Telix's osteomyelitis (bone infection) imaging agent, technetium-99m (99mTc) besilesomab, marketed under the brand name Scintimun®, is approved in 32 European countries and Mexico. Telix's miniaturized surgical gamma probe, SENSEI®, for minimally invasive and robotic-assisted surgery, is registered with the FDA for use in the U.S. and has attained a Conformité Européenne (CE) Mark for use in the European Economic Area. No other Telix product has received a marketing authorization in any jurisdiction. Visit for further information about Telix, including details of the latest share price, ASX and U.S. Securities and Exchange Commission (SEC) filings, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on LinkedIn, X and Facebook. Telix Investor Relations (Global)Ms. Kyahn WilliamsonTelix Pharmaceuticals LimitedSVP Investor Relations and Corporate CommunicationsEmail: Telix Investor Relations (U.S.)Annie KasparianTelix Pharmaceuticals LimitedDirector Investor Relations and Corporate CommunicationsEmail: Media Contact Eliza Schleifstein Eliza@ This announcement has been authorized for release by the Telix Pharmaceuticals Limited Board of Directors. Legal Notices Cautionary Statement Regarding Forward-Looking Statements. You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F filed with the SEC, or on our website. The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. The information and opinions contained in this announcement are subject to change without notification. To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement. This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as 'may', 'expect', 'intend', 'plan', 'estimate', 'anticipate', 'believe', 'outlook', 'forecast' and 'guidance', or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix's good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix's business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix's business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress, completion and results of Telix's preclinical and clinical trials, and Telix's research and development programs; Telix's ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix's product candidates, manufacturing activities and product marketing activities; Telix's sales, marketing and distribution and manufacturing capabilities and strategies; the commercialization of Telix's product candidates, if or when they have been approved; Telix's ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix's expenses, future revenues and capital requirements; Telix's financial performance; developments relating to Telix's competitors and industry; the anticipated impact of U.S. and foreign tariffs and other macroeconomic conditions on Telix's business; and the pricing and reimbursement of Telix's product candidates, if and after they have been approved. Telix's actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements. Trademarks and Trade Names. All trademarks and trade names referenced in this press release are the property of Telix Pharmaceuticals Limited (Telix) or, where applicable, the property of their respective owners. For convenience, trademarks and trade names may appear without the ® or ™ symbols. Such omissions are not intended to indicate any waiver of rights by Telix or the respective owners. Trademark registration status may vary from country to country. Telix does not intend the use or display of any third-party trademarks or trade names to imply any affiliation with, endorsement by, or sponsorship from those third parties. ©2025 Telix Pharmaceuticals Limited. All rights reserved. 1 Healthcare Common Procedure Coding System, refer to ASX disclosure 9 July 2025.2 Excludes revenue contribution from Illuccix sales.3 Revenue from date of RLS acquisition 27 January 2025.4 IND approved in China 22 July 2025; Clinical Trial Notification (CTN) approved in Japan 20 June 2025; Clinical Trial Application for Part 2 approved in Canada 22 May 2025.5 ID: NCT05663710.6 Refer to disclosure 13 May 2025.7 ID: NCT07052214.8 Magnetic resonance imaging.9 Imaging of prostate-specific membrane antigen with positron emission tomography.10 Subsequent to Telix disclosure on 23 June 2025, the FDA reclassified the submission to a PAS. The submission was made 5 June 2025.11 Positron Emission Tomography.12 Refer to ASX disclosure 20 June 2025.13 Prostate-specific membrane antigen.14 Brand name subject to final regulatory approval.15 Brand name subject to final regulatory approval.16 Prescription Drug User Fee Act. 17 Refer to ASX disclosures 20 February 2025. 18 See Guidance Disclaimer for further information.19 Telix ASX disclosure 20 December 2021.20 Telix ASX disclosure 21 March 2025.
Yahoo
15 minutes ago
- Yahoo
EV Connector Market worth $8.80 billion by 2032
DELRAY BEACH, Fla., July 22, 2025 /PRNewswire/ -- The EV connector market is projected to reach USD 8.80 billion by 2032, from USD 2.73 billion in 2025, with a CAGR of 18.2%, according to a new report by MarketsandMarkets. EV connectors for high-voltage systems are increasingly required to support miniaturization, weight reduction, and high-performance materials, alongside rising demand for high-bandwidth, low-latency transmission to support complex systems such as ADAS, battery management, vehicle lighting, and autonomous driving. As EVs rapidly adopt advanced driver-assistance and autonomous technologies, connectors must handle massive data flows, offering manufacturers opportunities for technological advancement. This trend is further accelerated by the shift toward zonal architectures and centralized computing, driving demand for multi-signal, high-speed connectors. Download an Illustrative overview: Browse in-depth TOC on "EV Connector Market" 307 - Tables 83 - Figures 305 - Pages Battery management systems are expected to show significant growth during the forecast period As EV battery architectures shift to more integrated, structural formats, demand for precise and reliable connectors has become more pronounced. In January 2024, JAE supplied HVIL-compliant signal connectors for BYD's Blade Battery, meeting high vibration tolerance and enabling stable BMS-to-cell communication. Similarly, in March 2024, TE Connectivity launched AMP+ high-voltage connectors for compact BMS setups in cylindrical and prismatic cells, offering enhanced creepage, clearance, and EMI shielding. These connectors featured improved creepage and clearance characteristics along with integrated shielding to minimize EMI, ensuring robust signal and power transmission in high-vibration environments. Such developments highlight a growing emphasis on connector precision and reliability as essential enablers of high-performance and safety-centric battery management systems in next-generation EVs. Board-to-board connection is expected to hold the largest share during the forecast period Board-to-board connectors establish direct electrical connections between two printed circuit boards (PCBs) within the same electronic module. These connectors support vertical, horizontal, and mezzanine stacking and are critical in applications such as digital cockpit units, centralized computing systems, and battery control modules. Their key advantages include enabling modular design, minimizing signal loss, and supporting high-speed data transmission in software-defined vehicle architectures. In June 2024, ERNI introduced zero-insertion-force board-to-board connectors for modular stacked ECU applications such as ADAS, infotainment, zonal architectures, and autonomous driving controllers, supporting multi-row layouts and shielded designs. Asia Pacific is expected to be the leading market during the forecast period Asia Pacific leads the global EV connector market, driven by robust manufacturing capabilities, increased EV production, and rapid innovation in vehicle electronics. As of 2024, the region accounted for over 55% of global EV output, supported by key automakers such as BYD, SAIC, Geely, Toyota, Hyundai, and Tata Motors. This strong presence fuels consistent demand for a broad spectrum of connectors from high-voltage components used in batteries and traction inverters to compact signal connectors for infotainment, ADAS, and zonal control systems in software-defined vehicles (SDVs). In July 2024, Sumitomo Electric began developing fiber-optic connectors to enable high-speed data transfer in SDVs through zonal E/E architectures. Adding to the region's momentum, Hyundai Mobis expanded its EV components plant in Ulsan in June 2024 to scale production of integrated connector modules, reinforcing Asia Pacific's position as the strategic hub for next-generation EV connector development. Key Market EV Connector Industry: Prominent players in the EV Connector Companies include as TE Connectivity Ltd. (Ireland), Aptiv (Ireland), Yazaki Corporation (Japan), Molex (US), and Hirose Electric Co., Ltd. (Japan), among others. Get 10% Free Customization on this Report: This report provides insights on: Analysis of key drivers (OEMs' emphasis on electrification of mid-segment and luxury vehicles, Rapid integration of ADAS and safety systems, Consumer preference for seamless and interactive driving experience), restraints (Volatility in Raw Material Prices), opportunities (Scaling of autonomous driving technologies, Shift toward advanced electrical/electronic (E/E) architecture), and challenges (Material degradation due to mechanical wear and thermal stresses, Transition from conventional connector systems to modular platform designs) influencing the growth of the EV connector market Product Development/Innovation: Detailed insights on upcoming technologies, R&D activities, and product launches in the EV connector market Market Development: Comprehensive information about lucrative markets – the report analyses the EV connector market across various regions Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the EV connector market Competitive Assessment: In-depth assessment of market shares, growth strategies, and service offerings of leading players like TE Connectivity (Ireland), Aptiv (Ireland), Yazaki Corporation (Japan), Molex (US), and Hirose Electric Co., Ltd. (Japan) in the EV connector market. Related Reports: Electric Vehicle Market EV Charging Station Market EV Cables Market Get access to the latest updates on EV Connector Companies and EV Connector Industry Growth About MarketsandMarkets™: MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report. MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe. Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem. The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing. Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts. To find out more, visit or follow us on Twitter , LinkedIn and Facebook . Contact:Mr. Rohan SalgarkarMarketsandMarkets™ INC. 1615 South Congress Ave. Suite 103, Delray Beach, FL 33445USA: +1-888-600-6441Email: sales@ Our Website: Logo: View original content: SOURCE MarketsandMarkets Sign in to access your portfolio